Original Source(s)
Related Content
Kidney Testing Gets Under the Skin
A microneedle platform captured a kidney injury biomarker from interstitial fluid
September 22, 2026
-
3 min
FDA clears targeted cholangiocarcinoma therapy
In the single-arm REFOCUS trial, 46% of patients responded to treatment, with a median response duration of 11.8 months.
September 24, 2026
-
2 min